Although pembrolizumab provides durable antitumor activity in several cancer types, including a complete response in some patients, even after discontinuation [15–17], the efficacy of anti-PD-1 antibody monotherapy is restricted to approximately 20–30% of treated patients in many clinical studies [14]. The gene discussed is PDCD1; the disease is cancer.